Quantitative determination of voriconazole by thionine reduction and its potential application in a pharmaceutical and clinical setting.
María Florencia LadettoJuan Manuel Lázaro-MartínezTomás Brito DevotoVíctor J BriceñoGuillermo Raúl CastroMaría Luján CuestasPublished in: Analytical methods : advancing methods and applications (2023)
Voriconazole (VCZ) is a triazolic drug used to treat serious fungal infections and invasive mycosis and has also been more recently used as a generic antifungal treatment. However, VCZ therapies can cause undesirable side effects and doses must be carefully monitored before administration to avoid or reduce severe toxic effects. Analytical techniques used to quantify VCZ are mostly based on HPLC/UV and often associated with multiple technical steps as well as expensive equipment. The present work aimed to develop an accessible and affordable spectrophotometric technique in the visible range ( λ = 514 nm) for the simple quantification of VCZ. The technique was based on VCZ-induced reduction of thionine (TH, red) to leucothionine (LTH, colorless) under alkaline conditions. The reaction showed a linear correlation over the range of 1.00 μg mL -1 to 60.00 μg mL -1 at room temperature, the limits of detection and quantification being 1.93 μg mL -1 and 6.45 μg mL -1 , respectively. VCZ degradation products (DPs) according to 1 H and 13 C-NMR spectrometric determinations not only showed good agreement with the ones previously reported (DP1 and DP2 - T. M. Barbosa, G. A. Morris, M. Nilsson, R. Rittner and C. F. Tormena, RSC Adv. , 2017, DOI: 10.1039/c7ra03822d), but also revealed a new degradation product (DP3). Mass spectrometry not only confirmed the presence of LTH as a result of the VCZ DP-induced TH reduction, but also revealed the formation of a novel and stable Schiff base as a reaction product between DP1 and LTH. The latter finding became significant as it stabilizes the reaction for quantification purposes, by hindering LTH ↔TH redox reversibility. This analytical method was then validated according to the ICH Q2 (R1) guidelines, and additionally, it could be demonstrated as applicable for the reliable VCZ quantification in commercially available tablets. Importantly, it also represents a useful tool for detecting toxic threshold concentrations in human plasma from VCZ-treated patients, alerting when these risky limits are exceeded. In this way, this technique independent from sophisticated equipment, highly qualifies as a low-cost, reproducible, trustable, and non-laborious alternative method for VCZ measurements from different matrices.
Keyphrases
- room temperature
- mass spectrometry
- liquid chromatography
- low cost
- high glucose
- end stage renal disease
- high performance liquid chromatography
- simultaneous determination
- drug induced
- rheumatoid arthritis
- diabetic rats
- ejection fraction
- chronic kidney disease
- single cell
- early onset
- endothelial cells
- gas chromatography
- prognostic factors
- emergency department
- tandem mass spectrometry
- systemic sclerosis
- quantum dots
- patient reported outcomes
- electron transfer
- adverse drug
- interstitial lung disease
- ankylosing spondylitis
- electronic health record